Gregory Morris is the Leader of Honigman's Life Sciences Intellectual Property Litigation Practice Group. Armed with more than 20 years of legal experience and a Ph.D. in Organic Chemistry from Northwestern University, Gregory’s practice focuses on pharmaceutical, biotechnology, and medical device patent litigation. He represents the industry's most sophisticated companies on the brand-side in Hatch-Waxman litigation and regularly litigates inter partes review (IPR) proceedings before the US Patent and Trademark Office (USPTO).

Lauded for his “strong technical expertise,” Gregory is considered to be “a great communicator who really digs into the science and explains things in layman's terms" (Chambers USA). In the first-ever successful defense of an Orange Book-listed patent in an IPR review, Gregory co-led a team of attorneys who represented a pharmaceutical company in the matter.

Gregory was recognized in the Crain’s Chicago Business 2019 list of “Notable Gen X Leaders in Law.” He has also been named a Patent Star by Managing IP each year since 2016 and a Life Sciences Star by LMG Life Sciences each year since 2017 for general patent litigation, patent strategy and management, and Hatch-Waxman patent litigation. In addition, IAM Patent 1000 recognized Gregory as one of the World’s Leading Patent Practitioners in 2020. Gregory has been quoted extensively in the media and writes and lectures widely on Hatch-Waxman litigation, biologics, and the PTAB.




Representative Matters

Significant representative matters include:

  • Ironwood Pharmaceuticals, Allergan, and Forest Laboratories

    Lead counsel for Ironwood Pharmaceuticals in Hatch-Waxman patent infringement litigation to protect clients’ prescription digestive drug, Linzess®.  Obtained consent judgments with injunctions against all defendants. (D. Del.) (Jan. 2020)
  • Merck and 3M
    Represented Merck and 3M in patent infringement litigation filed by AptarGroup relating to Merck’s prescription asthma product, Dulera®.  Achieved a complete victory whereby the asserted patents were invalidated in parallel IPRs and the complaint was dismissed with prejudice.  (PTAB) (Nov. 2019) (N.D. Ill.) (Jan. 2020)
  • Ironwood Pharmaceuticals
    Lead counsel for Ironwood Pharmaceuticals in IPR proceeding where Synergy Pharmaceuticals challenged client’s patent related to peptide therapeutics for the treatment of gastrointestinal disorders, obtaining an order terminating the proceedings.  (PTAB) (Nov. 2018)
  • Merck
    Co-lead counsel for Merck in IPR action against Apotex who was seeking to challenge a patent protecting Merck’s prescription product, Emend®.  Obtained a win whereby the institution of the IPR proceeding was denied.  (PTAB) (Oct. 2015)*
  • Galderma Labs. and Supernus Pharmaceuticals
    Represented Galderma and Supernus in parallel IPRs and Hatch-Waxman patent infringement litigation to protect clients’ prescription rosacea drug, Oracea®.  Co-led team that obtained IPR win after final written decision that was the first-ever successful defense of an Orange Book-listed patent in an IPR review. Obtained consent judgments with injunctions against all defendants.  (PTAB) (D. Del.)*  
  • Sanofi
    Represented Sanofi in Hatch-Waxman patent infringement litigation to protect client’s prescription digestive drug, Uroxatral ®.  Obtained a bench trial verdict at the close of evidence finding infringement and upholding the validity of the patents.  Obtained consent judgments with injunctions against all defendants.  (D. Del.)* 
  • Alexion Pharmaceuticals
    Represented Alexion in patent infringement litigation brought by PDL involving client's humanized antibody drug, Soliris®, obtaining a dismissal of all claims.  (D. Del.)* 
  • Forest Laboratories and Lundbeck A/S
    Represented Forest and Lundbeck in Hatch-Waxman patent infringement litigation to protect clients’ prescription digestive drug, Lexapro®.  Obtained consent judgments with injunctions against all defendants after bench trial.  (D. Del.)*

* Matter handled prior to joining Honigman

Prior Experience

  • Kirkland & Ellis LLP, Partner
  • Fish & Neave LLP, Associate/Patent Agent




Court Admissions



  • Chambers USA: America's Leading Lawyers, 2021
  • Managing Intellectual Property IP STARS, Recognized as a Patent Star, 2016-2022
  • IAM Patent 1000: The World’s Leading Patent Professionals, Recognized as one of the World’s Leading Patent Practitioners, 2020-2021
  • Crain’s Chicago Business Notable Gen X Leaders in Law, 2019
  • LMG Life Sciences, Recognized as a Life Sciences Star, 2017-2021
    • Recognized for General Patent Litigation, Patent Strategy & Management, Hatch-Waxman Patent Litigation

Professional & Community Involvement

New Jersey Intellectual Property Owners Association

New York Intellectual Property Law Association

The Richard Linn American Inn of Court

News & Insights


Seminars & Events

  • Event | American Conference Institute (ACI), New York, NY |
  • Speaker, Latest Trends and Strategic Considerations for Biotech Patent Challenges at the PTAB, Annual PTAB Webinar Series
    Webinar | |
  • Moderator, The PTAB Live! Practice, Policy, and Procedure in the New World of Pharmaceutical Patent Challenges, 16th Annual Paragraph IV Disputes
    Event | November 9-10, 2021 |
  • Conference Co-Chair and Speaker, The Hatch-Waxman Landscape: ANDAs, Economics, and Exclusivities, Passport to Proficiency on the Essentials of Hatch-Waxman and BPCIA
    Event | October 5-21, 2021 |
  • Moderator, Recent Developments in the Application of Section 112 to Genus Claims
    Event | |
  • Speaker, Challenging Patents on Reference Drugs: Litigation Strategies in the IPR Forum, 12th Summit on Biosimilars & Innovator Biologics
    Event | |
  • Moderator, You Can’t Go Home Again…Or can you? Establishing Venue in PIV Litigation Post- Valeant v. Mylan, 15th Annual Paragraph IV Disputes Symposium
    Event | |
  • Speaker, Examining the Latest Developments on the PTAB’s use of Discretionary Denials, Annual PTAB Webinar Series
    Event | |
  • Moderator, Bio Pharma: The Role of IP in Advancing Innovation and Collaboration in Response to the Pandemic
    Event | |
  • Moderator, PTAB Stats and Substance: Questions and Controversies Surrounding Filings, Judicial Appointments, Standing, and Expanded Powers
    Event | |
  • Speaker, Key Litigations and Decisions at the Federal Circuit, the District Courts and the PTAB Affecting the Biologics Landscape
    Event | |
  • Speaker, Virtual Courtroom: Navigating Paragraph IV Litigating From Home - Part I: Virtual Discovery, Paragraph IV on Virtual Trial COVID-19 Edition
    Event | |
  • Moderator, District Court Judges on the Present State of Paragraph IV Litigation: Filing Trends, Settlements and Timings
    Event | Chicago, IL | |
  • Speaker, The Costs and the Consequences of Determining Venue Post-TC Heartland
    Event | New York, NY | |
  • Speaker, The PTAB Live: A Hatch-Waxman Practitioner’s Guide to Practice, Procedure, IPRs and More in the World of Pharmaceutical Patent Validity Challenges
    Event | Chicago, IL | |
  • Speaker, Update on Hot-Button Litigation Issues and the Impact on Biologics Market and Strategies
    Event | New York, NY | |
  • Speaker, Mastering the Use of Experts in Parallel Proceedings
    Event | New York, NY | |
  • Speaker, PTAB Pharmaceutical Patent Invalidity Round-Up: Update on Wins, Losses, Appeals and Supreme Court Activity
    Event | Chicago, IL | |
  • Speaker, Untangling the Inner Workings of IPRs for Biosimilars
    Event | New York, NY | |
  • Speaker, PTAB Pharmaceutical Patent Invalidity Round-Up: Update on Wins, Losses and Appeals
    Event | New York, NY | |
  • Speaker, Antibodies in an Anti-Patent Climate: Weathering the Storm of Stricter Written Description and Enablement Requirements
    Event | New York, NY | |
  • Event | Chicago, IL | September 19-20, 2016 |
  • Speaker, Demystifying IPRs for Effective Use in the Biosimilars Landscape
    Event | New York, NY | June 13-15, 2016 |
  • Event | New York, NY | April 25-26, 2016 |
  • Speaker, PTAB Update: Where Are We After 3 Years of Orange Book Patent Challenges?
    Event | Iselin, NJ | |
  • Speaker, PTO Proceedings Update: The Continuing Use of IPR, PGR, and CBM Review in the Hatch-Waxman Arena
    Event | Chicago, IL | |
  • Speaker, Litigation Update
    Event | Dallas, TX | |
  • Speaker, PTO Proceedings Retrospect: Exploring the Growing Use of IPR, PGR and CBM review in Hatch-Waxman Litigation
    Event | New York, NY | |
  • Speaker, Exploring the Parallel World of IPR Proceedings
    Event | |
  • Speaker, Experts, Problems of Proof, Dispositive Motions and Markman Hearings: Addressing Common Dilemmas Encountered in A Paragraph IV Trial
    Event | Chicago, IL | |
  • Speaker, Patent Challenges Before the USPTO: Lessons Learned Since Their Inception Under the AIA
    Event | Boston, MA | |
  • Speaker, ANDA Litigation 101: Paragraph IV Disputes Primer
    Event | Chicago, IL | |
  • Speaker, Platform Patents and Antibodies: Specific Action Plans to Protect or Defend Patents Most Ripe for a Biosimilars First Wave Challenge
    Event | New York, NY | |
  • Speaker, Identifying Patents Which May be Ripe For Challenges of Invalidity and Non Infringement: Offensive and Defensive Strategies For Brand Names and Generics
    Event | Chicago, IL | |
  • Speaker, Practical Strategies for Dealing with the Written Description / Enablement Dichotomy: Satisfying Ever-Evolving § 112 Standards for Validity
    Event | |
  • Speaker, Preparing for the Coming Wave of Biosimilars Litigation
    Event | |
Jump to Page

By using this site, you agree to our Privacy Policy and our Disclaimer.